Answer:
from the intermembrane space to the matrix
Explanation:
In the electron transport chain (ETC), electrons flow from one protein complex to another. However, as this electrons are transfered, protons (H+) is built up from the intermembrane space of the mitochondria to the mitochondrial matrix.
Hence, according to this question, a proton gradient is formed when hydrogen ions (H+) are moving from the intermembrane space to the matrix of the mitochondrial.
Answer:
22
Explanation:
the thermometer goes by 2
Answer:
Mutualism
Explanation:
In biology, the term <em>symbiosis </em>refers to close and often long-term interactions between organisms that belong to different species. There are three main types of symbiotic relationships:
- mutualism - both organisms benefit from their relationship
- commensalism - one organism benefits, while the other doesn't benefit or suffer any harm
- parasitism - one organism causes harm to the other
In the given scenario, both the bird and plant benefit from their relationship. The bird gets food, while the plant reproduces more easily. This is why their relationship is an example of mutualism.
Answer:
The first person to observe cells was Robert Hooke. Hooke was an English scientist. He used a compound microscope to look at thin slices of cork.
Explanation:
Sorry if I am wrong let me know if I am.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
